;

BABRAHAM RESEARCH CAMPUS

THE BABRAHAM RESEARCH CAMPUS REMAINS OPEN FOR TENANT COMPANIES AND THEIR KEY WORKERS. Visitors and deliveries are to be kept to a minimum and social distancing advice adhered too.  Updates on the Babraham Institute can be found here.

The Babraham Research Campus is considered to be one of the UK’s leading campus' to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute. World class research and business come together to promote innovation and strengthen links between academia and the commercial world. The Babraham Research Campus is managed and developed by Babraham Bioscience Technologies Ltd (BBT).

Explore More

OVER 60
ORGANISATIONS ON SITE

COMMUNITY OF
1400 PEOPLE

CIRCA 300,000 SQ. FT.
LABORATORY & OFFICE
SPACE AVAILABLE

6 MILES FROM
CAMBRIDGE CENTRAL

START-UP MINDSET SCALE-UP CAPABILITY

Accelerate@Babraham

Provides support to the earliest stages of new life-science ventures, via easy-access laboratory and office space, combined with additional support programmes.

BABRAHAM RESEARCH CAMPUS IMPACT REPORT

In 2019, the Campus partners commissioned a report to evidence the impact the Campus has had on science, the economy and society. Click below to explore more.

Our Community

Babraham Research Campus is the location of choice to start and build life-science enterprises for over 60 bioscience organisations.

Lastest News & Opinion

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

Bicycle Therapeutics today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy

We are delighted to announce that we have entered into partnership with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, to explore new treatment options for people with epilepsy.

PHOREMOST AND XTALPI SIGN AI-BASED PHARMACEUTICAL DRUG DISCOVERY COLLABORATION AGREEMENT

PhoreMost and XtalPi Inc today announced they have entered into a drug discovery collaboration agreement.
Access to all our news and opinions

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;